Head and neck cancer
- Tumours of the head and neck include
- Eye and orbital tumours
- Oral cavity cancer
- Pharyngeal tumours
- Laryngeal tumours
- Supraglottic
- Glottic
- Subglottic
- Tumours of the nasal cavity and paranasal sinuses
- Tumours of the salivary gland
- Tumours of the thyroid gland
- Epidemiology
- Head and neck cancer is the 6th most common cancer worldwide
- Etiology
- Smoking
- Alcohol
- Poor oral hygiene
- EBV – for nasopharyngeal carcinoma
- HPV – for oropharyngeal and laryngeal cancer
- Pathology
- 80% are squamous cell
- 20% are adenocarcinoma, lymphoma, sarcoma, etc.
- Precancerous lesions
- Leukoplakia
- Erythroplakia
- Lichen planus
- Metastasizes most often to lung
- Clinical features
- Ulceration of mucosa
- Exophytic growth of mucosa
- Neck mass
- Sore throat
- Hoarseness
- Pain radiating into the ear
- Due to cranial nerve affection
- Dysphagia
- Diagnosis
- FNAB or direct excision biopsy
- Work-up after diagnosis
- CT with contrast or MRI of head and neck
- Laryngoscopy
- Neck US
- PET scan
- Treatment
- Majority of cases are treated with multiple modalities
- Surgery
- Only used if R0 resection with acceptable functional results is expected
- This means that surgery is not performed unless the surgeon believes that he can completely resect the tumour
- If early stage cancer -> transoral surgery (TORS)
- If cancer has spread to lymph nodes, neck dissection must be performed
- Modified radical neck dissection
- Selective neck dissection
- Surgery, especially of pharynx and larynx, impairs quality of life, which must be taken into account when deciding treatment modality
- Only used if R0 resection with acceptable functional results is expected
- Radiotherapy
- External beam radiotherapy or brachytherapy
- Can be given with curative or palliative intention
- Can be given postoperatively or primarily
- Primary radiotherapy alone is usually sufficient in
- Cancer of the lip
- Cancer of the nose
- Cancer of the floor of the mouth (brachytherapy)
- Cutaneous lymphoma
- Chemotherapy
- Cisplatin
- Taxanes
- 5-FU
- Biological and immunotherapy
- Cetuximab (anti-EGFR)
- Nivolumab (anti-PD-1)
- Pembrolizumab (anti-PD-1)